Modeling heart failure in animal models for novel drug discovery and development

被引:10
|
作者
Janssen, Paul M. L. [1 ,2 ,3 ]
Elnakish, Mohammad T. [1 ,2 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
基金
美国国家卫生研究院;
关键词
Animal model; human heart failure; ischemia; hypertension; contraction; LEFT-VENTRICULAR HYPERTROPHY; MYOCARDIAL-INFARCTION MODEL; CONTRACTILE DYSFUNCTION; ANGIOTENSIN-II; CARDIAC-FUNCTION; CANINE MODEL; IN-VIVO; FORCE; MOUSE; RAT;
D O I
10.1080/17460441.2019.1582636
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: When investigating drugs that treat heart diseases, it is critical when choosing an animal model for the said model to produce data that is translatable to the human patient population, while keeping in mind the principles of reduction, refinement, and replacement of the animal model in the research. Areas covered: In this review, the authors focus on mammalian models developed to study the impact of drug treatments on human heart failure. Furthermore, the authors address human patient variability and animal model invariability as well as the considerations that need to be made regarding choice of species. Finally, the authors discuss some of the most common models for the two most prominent human heart failure etiologies; increased load on the heart and myocardial ischemia. Expert opinion: In the authors' opinion, the data generated by drug studies is often heavily impacted by the choice of species and the physiologically relevant conditions under which the data are collected. Approaches that use multiple models and are not restricted to small rodents but involve some verification on larger mammals or on human myocardium, are needed to advance drug discovery for the very large patient population that suffers from heart failure.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 50 条
  • [11] Novel drug mechanisms in development for heart failure
    Khodjaev, Soidjon D.
    Teerlink, John R.
    Malik, Fady I.
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2014, 466 (06): : 1219 - 1225
  • [12] Novel drug mechanisms in development for heart failure
    Soidjon D. Khodjaev
    John R. Teerlink
    Fady I. Malik
    Pflügers Archiv - European Journal of Physiology, 2014, 466 : 1219 - 1225
  • [13] Mathematical modeling for novel cancer drug discovery and development
    Zhang, Ping
    Brusic, Vladimir
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (10) : 1133 - 1150
  • [14] Developing animal models of Zika virus infection for novel drug discovery
    Yde Ohki, Cristine Marie
    Benazzato, Cecilia
    Russo, Fabiele Baldino
    Baleeiro Beltrao-Braga, Patricia Cristina
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (06) : 577 - 589
  • [15] Animal models of urinary bladder cancer and their application to novel drug discovery
    Oliveira, Paula A.
    Arantes-Rodrigues, Regina
    Vasconcelos-Nobrega, Carmen
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (05) : 485 - 503
  • [16] Animal models of heart failure
    Arnolda, LF
    Llewellyn-Smith, IJ
    Minson, JB
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (03): : 403 - 409
  • [17] Animal models for drug discovery in dystonia
    Jinnah, H. A.
    Richter, Angelika
    Mink, Jonathon W.
    Caldwell, Guy A.
    Caldwell, Kim A.
    Gonzalez-Alegre, Pedro
    Cookson, Mark R.
    Breakefield, Xandra O.
    Delong, Mahlon R.
    Hess, Ellen J.
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (01) : 83 - 97
  • [18] Animal models for glioma drug discovery
    Jones, Terreia S.
    Holland, Eric C.
    EXPERT OPINION ON DRUG DISCOVERY, 2011, 6 (12) : 1271 - 1283
  • [19] Animal models of pain for drug discovery
    Joshi, Shailen K.
    Honore, Prisca
    EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (04) : 323 - 334
  • [20] Alternative Animal and Non-Animal Models for Drug Discovery and Development: Bonus or Burden?
    Freires, Irlan Almeida
    de Cassia Orlandi Sardi, Janaina
    de Castro, Ricardo Dias
    Rosalen, Pedro Luiz
    PHARMACEUTICAL RESEARCH, 2017, 34 (04) : 681 - 686